Entity

Time filter

Source Type

San Antonio, TX, United States

Nickisch K.,Evestra Inc. | Bode-Greuel K.M.,Bioscience Valuation BSV GmbH
Journal of Commercial Biotechnology | Year: 2013

The purpose of this study was to apply net present value (NPV) modelling to evaluate the financial attractiveness and business risk of different categories of biosimilars. Challenges and opportunities of biosimilars are compared with those of standard small molecule generics. Minimum peak sales levels are required to create financial value were determined in order to derive recommendations for the selection of commercially rewarding biosimilar development candidates. Source


Agyin J.K.,University of Texas Health Science Center at San Antonio | Santhamma B.,Evestra Inc. | Roy S.S.,University of Texas Health Science Center at San Antonio
Bioorganic and Medicinal Chemistry Letters | Year: 2013

Multiple myeloma (MM) is an incurable neoplasm characterized by devastating and progressive bone destruction. Standard chemotherapeutic agents have not been effective at significantly prolonging the survival of MM patients and these agents are typically associated with often severe, dose-limiting side effects. There is great need for methods to target the delivery of novel, effective cytotoxic agents specifically to bone, where myeloma cells reside. We have synthesized and evaluated the effects of the bone-targeted proteasome inhibitors PS-341-BP-1, PS-341-BP-2 and MG-262-BP on cell proliferation using the mouse 5TGM1 and human RPMI 8226 cell lines in vitro. The compounds exhibit strong cytotoxicity on MM cell lines and reduce the number of viable cells in a dose dependent manner. © 2013 Elsevier Ltd. All rights reserved. Source


Trademark
Evestra Inc. | Date: 2011-03-29

Pharmaceutical products for female health care, namely, pharmaceutical products for female fertility control, namely, oral pharmaceutical contraception products; pharmaceutical products for female fertility control, namely, pharmaceutical products for stimulating fertility; and pharmaceutical products for female contraception, namely, oral contraceptives.


Trademark
Evestra Inc. | Date: 2011-02-15

Pharmaceutical products for female health care, namely, pharmaceutical products for the treatment of breast cancer; pharmaceutical products for female fertility control, namely, oral pharmaceutical contraception products; pharmaceutical products for female fertility control, namely, pharmaceutical products for stimulating fertility; pharmaceutical products for female contraception, namely, oral contraceptives; pharmaceutical products for female hormone replacement therapy; pharmaceutical products for treating edometriosis; pharmaceutical products for treating fibroids; and pharmaceutical products for female oncology.


Patent
Evestra Inc. | Date: 2014-07-11

Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO

Discover hidden collaborations